Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalo Therapeutics, Inc. (NASDAQ: AVTX) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. Avalo is a Delaware-incorporated clinical stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, and its filings offer structured insight into both its clinical progress and corporate actions.
Recent Form 8-K filings referenced by the company cover a range of material events. These include announcements of quarterly financial results, where Avalo reports information such as cash, cash equivalents and short-term investments and summarizes research and development and general and administrative expenses. Other 8-Ks describe the posting of updated investor presentations, which outline the development strategy for AVTX-009 and the design of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS).
Additional 8-K reports detail governance and executive changes, such as the appointment of new directors and the hiring of senior executives like a Chief Business Officer. These filings summarize board decisions, committee assignments, equity awards, employment agreement terms and director compensation under Avalo’s non-employee director compensation plan. They also document director resignations and related amendments to outstanding equity awards.
For investors analyzing AVTX-009 and Avalo’s HS program, SEC filings complement press releases by providing formal descriptions of the LOTUS trial, including its randomized, double-blind, placebo-controlled Phase 2 design, dosing regimens and primary and secondary endpoints. They also link to exhibits such as press releases and investor presentations that expand on the company’s IL-1β scientific rationale.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools help summarize lengthy documents, highlight key sections on financial condition, clinical development updates, executive compensation and equity incentives, and make it easier to locate items such as Form 8-K exhibits and other relevant disclosures related to Avalo’s immune-mediated inflammatory disease programs.
Avalo Therapeutics reported that Chief Strategy Officer Jennifer Riley received a grant of stock options giving her the right to buy 95,000 shares of common stock. The award was reported at a price of $0.00 per share, reflecting a compensatory option grant rather than an open-market trade.
According to the disclosure, the option vests 25% on February 26, 2027, with the remaining shares vesting in equal monthly installments over the following three years, as long as she continues in service on each vesting date. This filing shows an increase in her derivative equity holdings through a grant/award acquisition, not a sale of existing shares.
Avalo Therapeutics, Inc. disclosed that Chief Medical Officer Mittie Doyle received a grant of stock options for 105,000 shares on February 26, 2026. The option has an exercise price reported as $0.0000 per share. Twenty‑five percent vests on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, conditioned on continued service.
Boyd Taylor reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that its Chief Business Officer, Boyd Taylor, received a grant of stock options covering 95,000 shares. The options were awarded as a derivative security and are held directly.
The award vests 25% on February 26, 2027, with the remaining options vesting in equal monthly installments over the following three years, subject to Boyd Taylor’s continued service on each vesting date.
Sullivan Christopher Ryan reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics reported that its Chief Financial Officer, Christopher Ryan Sullivan, received a grant of stock options representing 105,000 shares of common stock. These options were awarded on February 26, 2026 as an equity-based compensation grant.
The stock option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, conditioned on his continued service. After this grant, Sullivan held 105,000 stock options directly.
NEIL GARRY ARTHUR reported acquisition or exercise transactions in this Form 4 filing.
Avalo Therapeutics, Inc. reported that Chief Executive Officer Neil Garry Arthur received a grant of stock options covering 286,000 shares on February 26, 2026. The option vests 25% on February 26, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, subject to his continued service.
Avalo Therapeutics disclosed that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared beneficial ownership of 934,429 shares of common stock, representing 5.0% of the class.
The holdings are reported under a joint filing agreement dated 02/23/2026; voting and dispositive power are shown as shared among the filers.
OrbiMed Advisors LLC filed an amended Schedule 13G stating beneficial ownership of 1,187,300 shares of Avalo Therapeutics common stock, representing 6.4% of the class as of December 31, 2025.
OrbiMed reports zero sole voting or dispositive power and shared voting and dispositive power over all 1,187,300 shares, held on behalf of other persons entitled to dividends or sale proceeds. The firm certifies the position was not acquired to change or influence control of Avalo Therapeutics.
Avalo Therapeutics, Inc. received an updated ownership report from Caligan Partners LP and David Johnson. They report beneficial ownership of 881,533 shares of Avalo common stock, representing 4.9% of the outstanding shares, based on 18,133,968 shares outstanding as of November 3, 2025.
The shares are held through Caligan-managed funds and accounts, with shared voting and dispositive power over all reported shares. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avalo Therapeutics.
Point72 Asset Management and related entities report beneficial ownership of 627,502 shares of Avalo Therapeutics common stock, representing 3.5% of the class as of December 31, 2025. The stake is held through an investment fund managed by Point72, with no shares owned directly by the reporting persons.
Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen each report shared voting and dispositive power over these shares and no sole voting or dispositive power. They certify the investment is not for the purpose of changing or influencing control of Avalo Therapeutics.
Avalo Therapeutics, Inc. reported that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and principals Peter Kolchinsky and Rajeev Shah collectively beneficially owned 1,939,065 shares of common stock as of December 31, 2025, representing 9.99% of the company’s common shares.
The position consists of 662,968 common shares and Series C preferred stock convertible into additional common shares, but a 9.99% Beneficial Ownership Blocker limits how much preferred stock can be converted so their beneficial ownership does not exceed this threshold. The group classifies itself as a passive holder, certifying the securities are not held to change or influence control of Avalo Therapeutics.